[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "CDC, natural immunity not mentioned", "description": "This covid winter should be better than last\n\nDr. Anthony S. Fauci, President Biden\u2019s chief medical adviser\n\nhttps://www.nytimes.com/2022/11/22/us/politics/fauci-covid-winter-surge.html\n\nhttps://www.washingtonpost.com/health/2022/11/22/covid-bivalent-booster/?utm_campaign=wp_to_your_health&utm_medium=email&utm_source=newsletter&wpisrc=nl_tyh\n\nCombination of infections and vaccinations,\n\nenough community protection that we\u2019re not going to see a repeat of what we saw last year at this time\n\nRe bivalent effectiveness\n\nIt is clear now, despite an initial bit of confusion\n\nUnited States\n\nNearly $5 billion to buy 171 million bivalent boosters\n\n(Pfizer BioNTech, Moderna)\n\nHobson\u2019s choice\n\nDr. Ashish K. Jha, White House\u2019s Covid-19 response coordinator\n\nStill heavily promoting vaccination\n\nNothing I have seen in the subvariants makes me believe that we can\u2019t manage our way through it effectively, especially if people step up and get their vaccine\n\nSo far, 35 million people, (11% of over 5s) one bivalent shot\n\nhttps://www.cdc.gov/mmwr/volumes/71/wr/mm7148e1.htm?s_cid=mm7148e1_w\n\nEffectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection \u2014 Increasing Community Access to Testing Program, United States, September\u2013November 2022 \n\nThis is the clinical trial, previous work had only been based on antibodies\n\nBenefits are mentioned, adverse reactions are not\n\nAny adverse reactions not reported\n\nv-safe\n\nhttps://www.cdc.gov/mmwr/volumes/71/wr/mm7144a3.htm?s_cid=mm7144a3_w\n\nSystemic symptoms\n\nFatigue (30.0%\u201353.1%)\n\nHeadache (19.7%\u201342.8%)\n\nMyalgia (20.3%\u201341.3%)\n\nFever (10.2%\u201326.3%)\n\nReported inability to complete normal daily activities\n\n10.6% among aged over 65 years\n\n19.8% among aged 18\u201349 years\n\nBivalent boosters provided significant additional protection against symptomatic SARS-CoV-2 infection\n\nRelative vaccine effectiveness (rVE) of a bivalent booster dose,\n\ncompared with that of more than 2 monovalent vaccine doses,\n\n30% and 56% aged 18\u201349\n\nwith relative benefits increasing with time since receipt of the most recent monovalent vaccine dose. \n\nStaying up to date with COVID-19 vaccination, including getting a bivalent booster dose when eligible, is critical to maximizing protection against COVID-19\n\n350,000 tests at almost 10,000 retail pharmacies between Sept. 14 and Nov. 11\n\nRelative risk given\n\nAbsolute risk not given\n\nWhat about protection from severe disease?\n\nPaul Offit, director of the vaccine education center, professor of pediatrics, Children\u2019s Hospital of Philadelphia\n\nThe only reasonable goal is to prevent serious illness,\n\nWe are still waiting for one shred of evidence that this bivalent vaccine or any bivalent is better than what we had\n\nVirus continues to evolve\n\nThis should be a cautionary tale for what happens when you try to chase these variants\n\n\nCeline Gounder, infectious-disease specialist, Kaiser Family Foundation\n\nIt doesn\u2019t show the bivalents are better than the original boosters\n\n(but still advocated the bivalent shot)\n\nPei-Yong Shi, virologist, University of Texas Medical Branch\n\ndifficult to measure how well the updated boosters were working because so many people now had some immunity from earlier infections, \n\nincluding people who were never vaccinated or boosted. \n\nJohn P. Moore, virologist, Weill Cornell Medicine\n\nAre the boosters working better than the original shots?\n\nPersonally, I doubt there would have been much, if any, difference, but we may never know\n\nDr. Roby Bhattacharyya, infectious disease physician, Massachusetts General Hospital\n\nThis winter should be better than last\n\nwe\u2019re a more immune population\n\nChina\n\nhttps://www.reuters.com/world/china/chinas-daily-covid-cases-hit-record-high-2022-11-24/?utm_source=Sailthru&utm_medium=newsletter&utm_campaign=daily-briefing&utm_term=11-24-2022\n\nhttps://www.telegraph.co.uk/world-news/2022/11/24/iphone-factory-staff-offered-1400-leave-immediately-desperate/\n\nRecord high COVID-19 infections\n\nRigid zero-COVID policy\n\nCities nationwide imposing localised lockdowns\n\nMass testing, masks\n\nNo furlough scheme", "link": "https://www.youtube.com/watch?v=0hXESCSRyvY", "date_published": "2022-11-26 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "More vaccinated deaths than unvaccinated deaths from covid (US)", "description": "58% of covid US deaths now in the vaccinated\n\nKaiser Family Foundation vice president Cynthia Cox\n\nhttps://www.cdc.gov/vaccines/covid-19/effectiveness-research/protocols.html\n\nhttps://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status\n\nhttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/monitoring.html\n\nhttps://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/d6p8-wqjm\n\nhttps://www.washingtonpost.com/politics/2022/11/23/vaccinated-people-now-make-up-majority-covid-deaths/\n\n58% of coronavirus deaths in August were people who were vaccinated or boosted\n\n(people who had completed at least their primary series of vaccines)\n\nTherefore 42% coronavirus deaths in August were people who were unvaccinated\n\nFirst time there were more deaths covid deaths in the vaccinated versus the unvaccinated\n\nhttps://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5\n\nIn September 2021\nVaccinated people, 23% of coronavirus fatalities\n\nIn January and February 2022\n\nVaccinated people, 42% of coronavirus fatalities\n\nWe can no longer say this is a pandemic of the unvaccinated\n\n(who conducted the analysis on behalf of the Post)\n\nhttps://www.cdc.gov/mmwr/volumes/71/wr/mm7144a3.htm?s_cid=mm7144a3_w\n\nSafety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged \u226512 Years \u2014 United States, August 31\u2013October 23, 2022\n\nOn August 31, 2022\n\nFDA authorized bivalent, Pfizer-BioNTech and Moderna\n\nmRNA encoding the spike protein from original strain of SARS-CoV-2,\n\nand from Omicron BA.4 and BA.5\n\nAdvisory Committee on Immunization Practices (ACIP) recommended,\n\nall persons \u226512 years receive an age-appropriate bivalent mRNA booster dose\n\nv-safe\n\na voluntary smartphone-based U.S. safety surveillance system,\n\nestablished by CDC to monitor adverse events after COVID-19 vaccination\n\nAs of 3rd October, 10 million users\n\nhttps://icandecide.org/press-release/breaking-news-ican-obtains-cdc-v-safe-data/\n\nVaccine Adverse Event Reporting System (VAERS)\n\nTotal data, August 31\u2013October 23, 2022\n\n14.4 million received a bivalent Pfizer-BioNTech\n\n8.2 million adults (\u226518 years) a bivalent Moderna booster dose\n\nv-safe, among the 211,959 registrants (aged \u226512 years)\n\nAugust 31\u2013October 23, 2022\n\nReported in the week after vaccination\n\nInjection site reactions, 60.8%\n\nSystemic reactions, 54.8%\n\nFewer than 1% of v-safe registrants reported receiving medical care\n\nVaccine Adverse Event Reporting System (VAERS)\n\n5,542 reports of adverse events after bivalent booster vaccination (\u226512 years)\n\n95.5% of reports were nonserious\n\n4.5% were serious events\n\nHealth care providers and patients can be reassured that adverse events reported after a bivalent booster dose are consistent with those reported after monovalent doses. \n\nRelative risk\n\nAbsolute risk not given\n\nHealth impacts after COVID-19 vaccination are less frequent and less severe than those associated with COVID-19 illness (2).\n\nRelative risk\n\nAbsolute risk not given\n\n\nThis is their Reference 2\n\nBlock JP, Boehmer TK, Forrest CB, et al. Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination\u2014PCORnet, United States, January 2021\u2013January 2022. MMWR Morb Mortal Wkly Rep 2022;71:517\u201323. https://doi.org/10.15585/mmwr.mm7114e1 PMID:35389977\n\nmyocarditis; myocarditis or pericarditis; and myocarditis, pericarditis, or MIS,\n\nwithin 7-day or 21-day risk windows after the index date\n\nComparisons between after vaccine and after infection\n\nRelative risk\n\nAbsolute risk not given\n\nReview of v-safe Data\n\nDuring August 31\u2013October 23, 2022\n\n211,959 v-safe registrants had a bivalent booster\n\n1,464 (0.7%) were aged 12\u201317 years\n\n68,592 (32.4%) were aged 18\u201349 years\n\n59,209 (27.9%) were aged 50\u201364 years\n\n82.694 (39.0%) were aged \u226565 years\n\nFourth dose\n\n96,241; 45.4%\n\nFifth dose\n\n106,423; 50.2%\n\nIn the week after receipt of the bivalent booster dose\n\nLocal injection site reactions\n\n49.7% among aged \u226565\n\n72.9% among aged 18\u201349\n\nSystemic reactions\n\n43.5% among aged \u226565\n\n67.9% among aged 18\u201349\n\nSystemic symptoms\n\nFatigue (30.0%\u201353.1%)\n\nHeadache (19.7%\u201342.8%)\n\nMyalgia (20.3%\u201341.3%)\n\nFever (10.2%\u201326.3%)\n\nReported inability to complete normal daily activities\n\n10.6% among aged \u226565 years\n\n19.8% among aged 18\u201349 years\n\nReceipt of medical care\n\nReported by 0.8% of registrants", "link": "https://www.youtube.com/watch?v=Jb2YMvfvm_M", "date_published": "2022-11-25 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]